Manufacturers to gain more control and visibility over inventory and distribution process to better serve their customers
UPS Expands European Field Stocking Locations to Support Medical Device Industry
Saturday, July 2, 2016
Merck and Premier Inc. Collaborate to Prevent Fractures for Osteoporosis Patients | Merck Newsroom Home
Companies working alongside providers to develop solutions to serious public health needs
Merck and Premier Inc. Collaborate to Prevent Fractures for Osteoporosis Patients | Merck Newsroom Home
Merck and Premier Inc. Collaborate to Prevent Fractures for Osteoporosis Patients | Merck Newsroom Home
Alcoa: News: News Releases: Alcoa Awarded Multi-year, $470 Million Contract with Embraer
NEW YORK & SAO PAULO--(BUSINESS WIRE)--Lightweight metals leader Alcoa (NYSE:AA) today announced a long-term contract with Embraer – the leading manufacturer of commercial jets up to 130 seats – valued at approximately $470 million. Under the multiyear agreement, Alcoa will supply aluminum sheet and plate for Embraer’s new E2s, the second generation of its E-Jets family of commercial aircraft, a narrow-body medium-range jet airliner. The Embraer E-Jets E2 were launched at the Paris Airshow in 2013 and are scheduled to enter into service in 2018.
Alcoa: News: News Releases: Alcoa Awarded Multi-year, $470 Million Contract with Embraer
Alcoa: News: News Releases: Alcoa Awarded Multi-year, $470 Million Contract with Embraer
Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev | BMS Newsroom
NEW YORK & OXFORD, England--(BUSINESS WIRE)--Bristol-Myers Squibb Company(NYSE: BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an exclusive clinical collaboration agreement to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ enadenotucirev, a systemically administered oncolytic adenovirus therapeutic, in combination with Bristol-Myers Squibb’s Immuno-Oncology (I-O) agentOpdivo (nivolumab) to treat a range of tumor types in late-stage cancer patients.
Enadenotucirev is designed to have immune stimulating effects while Opdivo is designed to alleviate immune suppression. The clinical collaboration will support Phase 1 studies to determine whether combining these two agents can significantly improve the proportion of patients achieving objective tumor responses, the extent of tumor shrinkage, and/or the durability of responses.
Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev | BMS Newsroom
Friday, July 1, 2016
The Lau Hala Shops: An Exciting New Gathering Place in the Heart of Kailua
Transforming Former Kailua Macy's Building
Targeting Community-Focused Retailers and Restaurants
RSS Content| Alexander & Baldwin, Inc.
Targeting Community-Focused Retailers and Restaurants
RSS Content| Alexander & Baldwin, Inc.
Subscribe to:
Posts (Atom)